Diasorin, il tempismo in Borsa e l'ok dagli Usa per i test di qualità laboratoristica: 2025 chiuso alla grande Via libera per la diagnostica molecolare di Liaison Nes

#Diasorin e il tempismo di #Rosa. Su #Affaritaliani 30/12/25. #BorsaItaliana #FDA #internaldealing www.affaritaliani.it/economia/dia...

La maxi #plusvalanza dei #Denegri. Su #RepubblicaAF 22/09/25. #BorsaItaliana #Diasorin #Finde #bilancio2024

Age-Stratified Epidemiology of Respiratory Pathogens and the Value of Customizable Syndromic Testing Using the LIAISON PLEX Respiratory Flex Assay Molecular syndromic assays have improved respiratory diagnostics by enabling the simultaneous detection of multiple pathogens from a single sample. However, fixed-panel designs may not align with age-specific prevalence patterns or evolving epidemiologic trends, limiting clinical utility and reimbursement viability. In this study, 1520 positive nasopharyngeal swabs from symptomatic individuals collected during the 2022 to 2023 respiratory season were analyzed by using the LIAISON PLEX Respira...

Age-Stratified Epidemiology of Respiratory Pathogens and the Value of Customizable Syndromic Testing Using the LIAISON PLEX Respiratory Flex Assay. From @ampath.bsky.social member Kaisha Gonzalez at #Diasorin

Full text: https://loom.ly/i02MbNQ

Morgan Stanley favors DiaSorin over bioMérieux in EU biopharma stock shake-up Investing.com -- Morgan Stanley shifted its stance on European biopharma stocks, with a particular focus on diagnostics players bioMérieux (EPA:BIOX) and DiaSorin (BIT:DIAS), in a note dated Tuesday. The brokerage downgraded bioMérieux to “equal-weight” from “overweight” while upgrading DiaSorin (DIA) to “overweight” from “equal-weight” following first-half 2025 performance. The diagnostics market, while pressured by factors such as changes in Chinese reimbursement policy and currency effects, continued to show robust underlying growth, particularly in point-of-care and hospital-based testing. Strong U.S. and European testing volumes, partly supported by respiratory testing, contributed to this resilience. Morgan Stanley noted that sector valuation multiples remain elevated compared with broader European MedTech, reflecting investors’ preference for defensive revenue streams. For bioMérieux, the brokerage cited downside risks to earnings from a combination of factors: a slowdown in non-respiratory BioFire sales, weaker-than-expected flu season trends, significant China market headwinds, and foreign exchange pressures. Shares had outperformed peers by about 30% year-to-date, and at 28x forward earnings, Morgan Stanley said the stock already reflected its growth profile, capping re-rating potential. The price target was cut to €124, implying a slight downside, and the rating was revised to “equal-weight.” In contrast, DiaSorin’s shares had pulled back nearly 20% year-to-date, a decline Morgan Stanley viewed as excessive. The brokerage argued that the company’s specialty immunoassay portfolio and new molecular diagnostic launches offered sustainable midterm growth, forecasting organic sales growth of 8% in 2026, about 100 basis points ahead of consensus. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. Profitability tailwinds, including cost savings from the closure of its German manufacturing site and higher utilization of new platforms, were expected to support margin expansion. Trading at about 19x 2025 P/E, below its pre-Covid average and peers, DiaSorin was seen as undervalued. Morgan Stanley set a price target of €101, representing about 18% upside. That's one option, but what if there are better opportunities hiding in plain sight? Investing.com's ProPicks AI has identified growth stocks that often get overlooked by individual investors. Compare your choice against our global range of AI-selected picks - with 3 out of 4 beating their benchmark index year to date and 98% in the green. Get fresh new picks every month, now available at 50% off while our Summer Sale lasts. Hurry, offer ends soon!

Click Subscribe #MorganStanley #DiaSorin #bioMérieux #biopharma #stocks

Borsa: Milano fiacca con Diasorin e banche, corre Stellantis Male Bpm, Campari e Moncler. Debole Mps, bene Mediobanca e Stm

➡️ Leggi l'articolo: #Borsa #Milano #Diasorin #Stellantis #Banche

Age-Stratified Epidemiology of Respiratory Pathogens and the Value of Customizable Syndromic Testing Using the LIAISON PLEX Respiratory Flex Assay Molecular syndromic assays have improved respiratory diagnostics by enabling the simultaneous detection of multiple pathogens from a single sample. However, fixed-panel designs may not align with age-...

#ArticleinPress: Age-Stratified Epidemiology of Respiratory Pathogens and the Value of Customizable Syndromic Testing Using the LIAISON PLEX Respiratory Flex Assay. From @ampath.bsky.social member Kaisha Gonzalez at #Diasorin

Full text: www.jmdjournal.org/article/S152...

Diasorin, malumori tra i fondi. Da Allianz a Morgan Stanley: agli investitori non piacciono i maxi stipendi e bonus dei vertici I dettagli del verbale dell’assemblea degli azionisti dello scorso 28 aprile

#Diasorin, malumori tra i fondi. Su #Affaritaliani 18/06/25. #BorsaItaliana #assemblea #remunerazioni www.affaritaliani.it/economia/dia...